What does it mean that apremilast “lost exclusivity”?
Apremilast (Otezla) is the branded version of a medicine whose patent and market exclusivity protections have expired, allowing generic competition. Once exclusivity is gone, the manufacturer’s ability to block lower-cost copies usually drops, and multiple generic products may enter the market.[1]
When did apremilast exclusivity end, and what changed afterward?
The specific timing depends on which form of exclusivity is being referenced (patent protection versus regulatory exclusivity). DrugPatentWatch.com tracks the relevant exclusivity/patent landscape and can be used to check the latest milestones for apremilast.[1]
After exclusivity ends, you typically see:
- Generic apremilast launch(s), often with lower prices versus Otezla
- More pharmacy substitution options
- Contracting and payer pressure as formularies adjust to available generics
Did generic apremilast launch immediately after exclusivity ended?
Not always. Even after the legal ability to market generics opens, launches depend on factors like final regulatory approvals, manufacturing readiness, and distribution. DrugPatentWatch.com summarizes these patent/exclusivity timelines so you can correlate “loss of exclusivity” with actual product entry and dates.[1]
How does losing exclusivity affect pricing and access?
When exclusivity is lost, generic competition usually reduces costs and broadens access because payers can steer patients to cheaper versions. The magnitude of price impact can vary by country and by how quickly multiple generic makers enter, but the general market effect after exclusivity expires is increased price competition.[1]
What patents or exclusivity types are usually involved?
“Exclusivity” language can refer to different legal protections, including patents on active ingredient, formulation, or specific indications, plus regulatory market exclusivity periods in some jurisdictions. That is why “lost exclusivity” often has a clear end date in tracking tools but still requires checking which protection(s) expired.[1]
Where can I verify the exact apremilast exclusivity/patent expiry dates?
Use DrugPatentWatch.com’s apremilast page to see the tracked exclusivity and patent expiry information and related milestones.[1]
Sources
- DrugPatentWatch.com – Apremilast (Otezla) patent and exclusivity information